PLATELET TRANSFUSION RESPONSE IN HEMATOLOGICAL PATIENTS WITH ANTI-HLA ANTIBODIES AT NATIONAL INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION FROM 2020 TO 2024
Main Article Content
Abstract
Objectives: To evaluate platelet transfusion response in patients with hematologic diseases and anti-HLA antibodies at the National Institute of Hematology and Blood Transfusion from 2020 to 2024.
Methods: A longitudinal descriptive study was conducted among 68 patients with anti-HLA antibodies who had indications for platelet transfusion during the period from 2020 to 2024 at the National Institute of Hematology and Blood Transfusion.
Results: Among the 68 patients, 41 (60.29%) experienced platelet refractoriness. A total of 473 platelet transfusions were evaluated, of which 170 (35.94%) were refractory episodes (24-hour CCI < 5,000/µL). The proportions of patients with platelet refractoriness increased among age groups, peaked at patients with both class I and class II anti-HLA antibodies (65.79%). The difference among the three antibody groups (class I alone, class II alone, and combined class I and II) was not statistically significant (p = 0.554).
Conclusions: Platelet refractoriness was common among patients with hematologic diseases and anti-HLA antibodies. The degree of refractoriness varied considerably among individuals and tended to be higher among both class I and class II anti-HLA antibodies with no statistically significant difference observed.
Keywords
Anti-HLA antibodies, platelet transfusion, platelet refractoriness
Article Details
References
2. Brown CJ, Navarrete CV. Clinical relevance of the HLA system in blood transfusion. Vox Sanguinis. 2011;101(2):93-105.
3. Semple JW, Speck ER, Cosgrave D, Lazarus AH, Blanchette VS, Freedman J. Extreme Leukoreduction of Major Histocompatibility Complex Class II Positive B Cells Enhances Allogeneic Platelet Immunity. Blood. 1999;93(2):713-20.
4. Couvidou A, Rojas-Jiménez G, Dupuis A, Maître B. Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: From mechanisms and determinants to therapeutic prospects. Frontiers in Immunology. 2023;14.
5. Youk H-J, Hwang S-H, Oh H-B, Ko D-H. Evaluation and management of platelet transfusion refractoriness. Blood Research. 2022;57(S1):S6-S10.
6. Triulzi DJ, Kleinman S, Kakaiya RM, Busch MP, Norris PJ, Steele WR, et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion‐related acute lung injury risk reduction strategy. Transfusion. 2009;49(9):1825-35.
7. Belizaire R, Makar RS. Non-Alloimmune Mechanisms of Thrombocytopenia and Refractoriness to Platelet Transfusion. Transfusion Medicine Reviews. 2020;34(4):242-9.
8. Li X, Liu Q, Dong J, Hong Y, Xin C, Guo J, et al. Existence and significance of anti-HLA-C autoantibodies to primary and persistent platelet transfusion refractoriness in patients with hematologic disorders: a retrospective study from a single centre. Annals of Medicine. 2024;57(1).